[go: up one dir, main page]

AU2001245535A1 - Human fgf-23 gene and gene expression products - Google Patents

Human fgf-23 gene and gene expression products

Info

Publication number
AU2001245535A1
AU2001245535A1 AU2001245535A AU4553501A AU2001245535A1 AU 2001245535 A1 AU2001245535 A1 AU 2001245535A1 AU 2001245535 A AU2001245535 A AU 2001245535A AU 4553501 A AU4553501 A AU 4553501A AU 2001245535 A1 AU2001245535 A1 AU 2001245535A1
Authority
AU
Australia
Prior art keywords
gene
expression products
human fgf
gene expression
fgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001245535A
Inventor
Nobuyuki Itoh
Michael W. Kavanaugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
Novartis Vaccines and Diagnostics Inc
Original Assignee
Kyoto University NUC
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC, Chiron Corp filed Critical Kyoto University NUC
Publication of AU2001245535A1 publication Critical patent/AU2001245535A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001245535A 2000-03-08 2001-03-07 Human fgf-23 gene and gene expression products Abandoned AU2001245535A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18785400P 2000-03-08 2000-03-08
US60/187,854 2000-03-08
US23336800P 2000-09-18 2000-09-18
US60/233,368 2000-09-18
US25164900P 2000-12-05 2000-12-05
US60/251,649 2000-12-05
PCT/US2001/007469 WO2001066596A2 (en) 2000-03-08 2001-03-07 Human fgf-23 gene and gene expression products

Publications (1)

Publication Number Publication Date
AU2001245535A1 true AU2001245535A1 (en) 2001-09-17

Family

ID=27392306

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001245535A Abandoned AU2001245535A1 (en) 2000-03-08 2001-03-07 Human fgf-23 gene and gene expression products

Country Status (3)

Country Link
US (1) US20030105302A1 (en)
AU (1) AU2001245535A1 (en)
WO (1) WO2001066596A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2344679T3 (en) * 2000-08-11 2010-09-03 Kyowa Hakko Kirin Co., Ltd. POLYPEPTIDES THAT CONTROL THE METABOLISM OF PHOSPHORIC ACID, THE METABOLISM OF CALCIUM, THE METABOLISM OF CALCIFICATION AND VITAMIN D AND DNA MOLECULES THAT CODIFY THEM.
CA2443719A1 (en) * 2001-04-26 2002-11-07 Geneprot, Inc. Human fibroblast growth factor-related compositions
ATE441666T1 (en) * 2001-12-28 2009-09-15 Kyowa Hakko Kirin Co Ltd ANTIBODIES AGAINST FIBROBLAST GROWTH FACTOR 23
CA2468610A1 (en) * 2002-01-15 2003-07-24 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
DE602004032457D1 (en) * 2003-11-07 2011-06-09 Novartis Ag NTEN
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
PT2726511T (en) 2011-07-01 2019-10-14 Ngm Biopharmaceuticals Inc Compositions, uses and methods for treatment of metabolic disorders and diseases
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP4083221A1 (en) 2012-12-27 2022-11-02 NGM Biopharmaceuticals, Inc. Chimeric fgf19 peptides for use in treating bile acid disorders
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
SG11201602870YA (en) 2013-10-28 2016-05-30 Ngm Biopharmaceuticals Inc Cancer models and associated methods
PT3097122T (en) 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
JP2017517272A (en) 2014-03-28 2017-06-29 ニューヨーク・ユニバーシティ FGF23 fusion protein
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
UA123763C2 (en) 2014-10-23 2021-06-02 Енджіем Байофармасьютикалз, Інк. PHARMACEUTICAL COMPOSITION FOR CONTROL OR TREATMENT OF FGF19 DISEASE OR DISORDER
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
US10744185B2 (en) 2015-11-09 2020-08-18 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of pruritus
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU761340B2 (en) * 1998-06-02 2003-06-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000060085A1 (en) * 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
JP2004522402A (en) * 1999-06-02 2004-07-29 ジェネンテック・インコーポレーテッド Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1246843A1 (en) * 2000-01-05 2002-10-09 ZymoGenetics, Inc. Novel fgf homolog zfgf12
JP2005508131A (en) * 2000-02-15 2005-03-31 アムジェン インコーポレイテッド Fibroblast growth factor-23 molecule and uses thereof

Also Published As

Publication number Publication date
WO2001066596A3 (en) 2002-03-28
WO2001066596A2 (en) 2001-09-13
US20030105302A1 (en) 2003-06-05
WO2001066596A9 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
AU2001249125A1 (en) Human fgf-23 gene and gene expression products
AU2001245535A1 (en) Human fgf-23 gene and gene expression products
AU2001285047A1 (en) Human genes and gene expression products
AU2001245619A1 (en) Human genes and gene expression products
AU6069300A (en) Novel human genes and gene expression products
AU4187499A (en) Human genes and gene expression products v
AU4053699A (en) Novel human genes and gene expression products
AU7748200A (en) Hypoxia-related human genes, proteins, and uses thereof
AU2001282288A1 (en) Kaolin products and their use
AU4329300A (en) Human mesenchymal dnas and expression products
AU3072500A (en) Rhamnosyl-transferase gene and uses thereof
AU1101901A (en) Human fgf-20 gene and gene expression products
AU2001226922A1 (en) Cancer associated genes and their products
AU6263999A (en) Human genes and gene expression products
AU2001270478A1 (en) Gene expression in biological conditions
AU2001274566A1 (en) Novel protein and dna thereof
AU2001287269A1 (en) Human genes and expression products
AU2001268053A1 (en) Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
AU2001264955A1 (en) Human cyslt2 nucleic acids, polypeptides, and uses thereof
AU1894601A (en) Novel gene and use thereof
AU2001264245A1 (en) Novel enzyme gene and its expression product
AU6424501A (en) Novel enzyme gene and its expression product
AU6773200A (en) Egfh2 genes and gene products
AU3900000A (en) Human fgf gene and gene expression products
AU4834799A (en) Human az-1 gene, variants thereof and expressed gene products